Larimar Therapeutics closes $161.8M public offering of 19.7M shares at $8.74

Larimar Therapeutics, Inc.

Offered 17,162,472 shares plus 2,574,370 option shares exercised immediately.
Net proceeds ~$161.8M after underwriting discounts and estimated expenses.
Joint bookrunners: Leerink Partners, Citigroup, Guggenheim Securities.
All shares sold by company; offering closed February 16, 2024.
Proceeds will support clinical development of nomlabofusp (CTI-1601) and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Larimar Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein valued at approximately $161.8 million (effective 2024-02-14).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein
Value: approximately $161.8 million
Effective: 2024-02-14

Exact text from the filing

On February 14, 2024, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 17,162,472 shares (the “ Shares ”) of the common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $8.74 per share, less the underwriting discounts and commissions.

View on SEC.gov

Browse all material agreements →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-038473

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.